California Public Employees Retirement System Seagen Inc. Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	BUY	$191.51 - $216.16 $35.8 Million - $40.4 Million	186,885 Added 73.38%	441,561 $93.7 Million
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $7.82 Million - $8.59 Million	-41,662 Reduced 14.06%	254,676 $49 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $19.2 Million - $30.6 Million	-150,479 Reduced 33.68%	296,338 $60 Million
Q4 2022 Feb 08, 2023	SELL	$117.37 - $139.17 $10.4 Million - $12.3 Million	-88,250 Reduced 16.49%	446,817 $57.4 Million
Q3 2022 Nov 09, 2022	SELL	$135.27 - $180.11 $20.7 Million - $27.5 Million	-152,807 Reduced 22.21%	535,067 $73.2 Million
Q2 2022 Aug 10, 2022	SELL	$108.81 - $179.33 $35.5 Million - $58.6 Million	-326,540 Reduced 32.19%	687,874 $122 Million
Q1 2022 May 04, 2022	SELL	$119.61 - $157.85 $2.33 Million - $3.08 Million	-19,504 Reduced 1.89%	1,014,414 $146 Million
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $1.44 Million - $1.93 Million	-10,110 Reduced 0.97%	1,033,918 $160 Million
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $3.86 Million - $4.6 Million	27,072 Added 2.66%	1,044,028 $177 Million
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $4.86 Million - $5.79 Million	35,967 Added 3.67%	1,016,956 $161 Million
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $2.42 Million - $3.36 Million	-17,623 Reduced 1.76%	980,989 $136 Million
Q4 2020 Feb 02, 2021	BUY	$164.63 - $211.93 $164 Million - $212 Million	998,612 New	998,612 $175 Million

Others Institutions Holding SGEN

# of Institutions

Shares Held

1.26M

Call Options Held

23K

Put Options Held

55.2K

View Full List

About Seagen Inc.

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

More about SGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account